Star Sports Medicine Co Ltd (Ticker: 1609 HK) is a China-based medical device company specializing in clinical sports medicine solutions. Star Sports Medicine plans to list on the Hong Kong Stock Exchange on May 5, 2026, planning to offer 8.42 million shares at a price of HKD 98.50, raising HKD 829.55 million (USD 105.88 million). The company is expected to have a market capitalization of USD 689.37 million at the time of the IPO.

According to the prospectus, Star Sports Medicine plans to use the IPO proceeds for research and development, product capacity expansion, brand promotion, business development, working capital, and strategic acquisitions. As reported in the prospectus, the company offers holistic solutions for the treatment of injuries to soft tissues, including rotator cuffs, ligaments, and meniscus. Reportedly, it is the largest domestic sports medicine implants and instruments provider in China, holding an approximate 6.5% market share. The offering is structured as an H Share listing. CCB International Capital and CITIC Securities are serving as the joint sponsors for the deal, alongside other joint managers including CLSA, CMBC Securities, and China Galaxy International.

Cofoe Medical Technology Co., Ltd. (Ticker: 1187 HK) is a Chinese company focusing on the manufacturing and distribution of home care medical devices, such as glucose meters, blood pressure devices, wheelchairs and hospital beds.

Cofoe Medical Technology plans to list on the Hong Kong Exchange on May 6, 2026, planning to offer 27.0 million shares at an expected price of HKD 39.33, raising approximately HKD 1.06 billion (USD 135.5 million). According to published terms, BNP Paribas Securities Asia, Futu Securities International, and Huatai Financial Holdings are serving as the joint managers for the IPO.

As reported in the prospectus, the firm ranked second among home care medical device providers in China based on 2024 domestic revenue, capturing a 2.1% market share in a highly competitive sector. The company operates an integrated research, development, manufacturing, and distribution model. Its extensive product portfolio addresses diverse healthcare scenarios and encompasses over 200 categories with more than 10,000 SKUs. While the Chinese mainland represents its primary geographic segment, Cofoe Medical Technology is actively expanding its sales footprint into international markets, including Hong Kong, the United States, and the United Kingdom.

Silex Microsystems AB (Ticker: SILEX SS) is a Swedish semiconductor company operating as a MEMS foundry, manufacturing micro-electromechanical systems in specialized wafer fabrication facilities. Silex plans to list its ordinary shares on Nasdaq Stockholm on May 7, 2026. According to published terms, the company is offering 24.60 million shares at SEK 81.00 per share, raising SEK 1.99 billion, or approximately $217 million.

The offering consists of 12.35 million primary shares, representing 50.2% of the offer, and 12.25 million secondary shares sold by Global Access Electronics Ltd., a wholly owned subsidiary of Sai MicroElectronics Inc. Following the offering, Sai MicroElectronics’ ownership is expected to fall to 9.9% of outstanding ordinary shares. According to the prospectus, Silex intends to use the IPO proceeds primarily to support its strategy of establishing U.S. manufacturing capacity, including a potential acquisition and conversion of an East Coast U.S. IC fab into a MEMS fab. ABG Sundal Collier, Avanza, Kepler Cheuvreux, Nordea and SEB are managing the offering.

HawkEye 360, Inc. (Ticker: HAWK US) is an American defense technology company incorporated in Delaware that offers a satellite signal-processing platform focused on RF signals intelligence and commercial SIGINT data for U.S. government agencies, allied governments and intelligence customers. The company operates more than 30 satellites in orbit and uses proprietary algorithms, sensors and an RF emitter database to deliver signal analytics across classified and unclassified environments.

HawkEye 360 plans to list on the NYSE on May 7, 2026. According to published IPO terms, the company is offering 16.0 million shares at $24.00 to $26.00 per share, raising approximately $400 million at the $25.00 midpoint. The estimated market capitalization is around $2.3 billion. Goldman Sachs, Morgan Stanley, RBC Capital Markets, Jefferies, BofA Securities, Baird, Raymond James and William Blair are joint managers. Founded in 2015, HawkEye 360 completed its acquisition of Innovative Signal Analysis, Inc. in December 2025, adding classified signal-processing technologies and expanding its government-focused capabilities.

Suja Life, Inc. (Ticker: SUJA US) is an American beverage company incorporated in Delaware that sells cold-pressed juices, wellness shots and functional sodas through its Suja Organic, Vive Organic and Slice brands. The company operates a vertically integrated cold-pressed beverage platform, with products available in more than 37,000 stores, and focuses on functional, better-for-you beverages across health and wellness consumer occasions.

Suja Life plans to list on NASDAQ on May 7, 2026. According to published IPO terms, the company is offering 8.89 million shares at $21.00 to $24.00 per share, raising approximately $200 million at the indicated terms. The estimated market capitalization is about $869 million. Goldman Sachs, Jefferies, William Blair, BofA Securities and Evercore ISI are joint managers.

Ldrobot (Ticker: 1236 HK) is a Chinese company specializing in intelligent robot visual perception technology, LiDAR products, and complete robotic systems such as robot lawn mowers. Structured as an H-share entity, Ldrobot plans to list on the HKEX on May 11, 2026, planning to offer 33,333,400 shares at a price range of HKD 24.00 to HKD 30.00. This offering will raise between HKD 800.0 million and HKD 1.0 billion (approximately USD 102.6 million to USD 128.2 million).

At this proposed price range, the company's valuation will reach a market capitalization of HKD 8.0 billion to HKD 10.0 billion (roughly USD 1 billion to USD 1.3 billion). According to the prospectus, Ldrobot plans to use the IPO proceeds for research and development, product capacity expansion, brand promotion, business development, working capital, and potential strategic acquisitions.

The company reportedly supplies technology to several of the world's top household and commercial service robot manufacturers. Haitong International Capital Limited and Guotai Junan Capital Limited are serving as the joint sponsors for the IPO, supported by a syndicate of underwriters including China International Capital Corporation and Futu Securities International.